Similar articles

• [Telbivudine in the management of HIV/HBV coinfection. Treating hepatitis B without HIV trouble].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2009 Apr 30;151(18):62-3. MMW Fortschr Med. 2009. PMID: 19769080 German. No abstract available.
• Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.

  Sheng WH, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, Chen PJ, Chang SC. Sheng WH, et al. Clin Infect Dis. 2007 Apr 1;44(7):988-95. doi: 10.1086/511867. Epub 2007 Feb 20. Clin Infect Dis. 2007. PMID: 17342655
• [Treatment of chronic hepatitis B].

  Mauss S. Mauss S. MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:48-51. MMW Fortschr Med. 2008. PMID: 19031564 German. No abstract available.
• [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

  Panel de expertos de Gesida y Plan Nacional sobre el Sida. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
• Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.

  Locarnini S, Warner N. Locarnini S, et al. Antivir Ther. 2007;12 Suppl 3:H15-23. Antivir Ther. 2007. PMID: 18284179 Review.